ACE2: A novel therapeutic target for cardiovascular diseases
- 30 June 2006
- journal article
- review article
- Published by Elsevier BV in Progress in Biophysics and Molecular Biology
- Vol. 91 (1-2), 163-198
- https://doi.org/10.1016/j.pbiomolbio.2005.05.011
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Vascular chymase: pathophysiological role and therapeutic potential of inhibitionCardiovascular Research, 2004
- Robust and Efficient Regulation of Transgene Expression in Vivo by Improved Tetracycline-Dependent Lentiviral VectorsMolecular Therapy, 2002
- EXPERIMENTAL KALLIKREIN GENE THERAPY IN HYPERTENSION, CARDIOVASCULAR AND RENAL DISEASESPharmacological Research, 1997
- Double‐Blind Comparison of Losartan, Lisinopril, and Metolazone in Elderly Hypertensive Patients with Previous Angiotensin‐Converting Enzyme Inhibitor‐Induced CoughThe Journal of Clinical Pharmacology, 1997
- Valsartan, a New Angiotensin II Receptor Antagonist: A Double‐Blind Study Comparing the Incidence of Cough with Lisinopril and HydrochlorothiazideThe Journal of Clinical Pharmacology, 1997
- A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: Angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11Life Sciences, 1993
- Heredity and hypertension: Impact on metabolic characteristicsAmerican Heart Journal, 1992
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureThe New England Journal of Medicine, 1987
- Implications of local angiotensin production in cardiovascular physiology and pharmacologyThe American Journal of Cardiology, 1987
- Dietary Protein Intake and the Progressive Nature of Kidney Disease:The New England Journal of Medicine, 1982